报告题目：Nanoparticles for Probing Biological Systems at Single Molecule and Single Cell Level
报告人： Prof. Gang Ruan
Nanometer-sized particles (nanoparticles) made of semiconductors, metal oxides, metals, polymers and lipids possess special physical, structural, chemical, and biological properties, which offer great potentials in sensing, imaging, and therapy for biomedicine. This talk will focus on development of quantum dots (semiconductor nanocrystals) and composite nanoparticles (nanoparticle integrating more than one component nanoparticles) for sensing and manipulation of single molecules and single cells.
Prof. Gang Ruan was trained as a traditional chemical engineer in his bachelor (Harbin Engineering University, China, with Drs. Hongxing Dong and Renqiu Jiang) and masters (Tianjin University, China, with Dr. Yaquan Wang) degree studies. He started to move into the field of nanobiotechnology when he pursued his PhD degree in the National University of Singapore, where he worked on polymer and lipid micro/nanoparticles for controlled drug delivery (with Dr. Sishen Feng). Dr. Ruan moved to the US in 2004 to work with Dr. Shuming Nie at Emory University and Georgia Institute of Technology as a postdoctoral fellow on quantum dots for molecular and cellular imaging. From 2007-2012 he worked at the Ohio State University as a research scientist (with Dr. Jessica Winter) leading the efforts of developing composite nanoparticles for a wide spectrum of biomedical applications. In 2013 Dr. Ruan received a “National Thousand Young Global Talent” (“Qian-Ren”) award from the Chinese Central Government to join the newly founded College of Engineering and Applied Sciences in Nanjing University, China as a professor of Biomedical Engineering. Prof. Ruan has published approximately 30 papers, many of which in high impact journals. In technology commercialization, he co-founded a company in 2012 that won the 1st place of Ohio State’s Fisher Business Plan Competition and NSF’s Innovation Corps and SBIR grants, and attracted private venture capitals.